Curated News
By: NewsRamp Editorial Staff
September 09, 2024
Clene (NASDAQ: CLNN) Developing Breakthrough Treatment for Neurodegenerative Diseases
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Clene's focus on improving mitochondrial health with CNM-Au8 gives them an advantage in treating neurodegenerative diseases.
- CNM-Au8 targets the nicotinamide adenine dinucleotide pathway to restore and protect neurological function in ALS, MS, and Parkinson's disease.
- Clene's innovative treatment offers new hope for patients with neurodegenerative diseases, making tomorrow better than today.
- The global therapeutics market for neurogenerative diseases is projected to grow substantially, driven by new therapies and a rising geriatric population.
Impact - Why it Matters
This news matters because Clene's innovative treatment, CNM-Au8, offers new hope for patients with ALS, MS, and Parkinson's disease. The company's focus on improving mitochondrial health and targeting the NAD+ pathway has the potential to transform the treatment of neurodegenerative diseases, impacting millions of people worldwide.
Summary
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is making significant strides with its lead candidate, CNM-Au8. This innovative treatment focuses on targeting the nicotinamide adenine dinucleotide (NAD+) pathway, which is critical for many mitochondrial functions, including energy production and redox homeostasis. Through this novel mechanism, CNM-Au8 restores and protects neurological function, offering new hope for patients with conditions like amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and Parkinson’s disease. Clene is preparing Phase 3 trials of CNM-Au8 in MS and ALS.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene (NASDAQ: CLNN) Developing Breakthrough Treatment for Neurodegenerative Diseases
